Abstract | PURPOSE, PATIENTS, AND METHODS: RESULTS:
Ketoconazole clinically cured 16 of 21 (76%) patients. The lesions on nine patients healed by 1 month after therapy, and the lesions healed by 3 months after therapy on the other seven patients. Side effects were limited to a 27% incidence of mild, reversible hepatocellular enzyme elevation and an asymptomatic, reversible, approximately 70% decrease in serum testosterone in all patients. Pentostam cured 13 of 19 (68%) patients; the lesions on seven patients healed by the end of therapy, and the lesions on four other patients healed by 1 month after the end of therapy. Side effects were a 47% incidence of mild, reversible hepatocellular enzyme elevation and the morbidity due to 20 intramuscular injections in almost all patients. The placebo group of 11 patients had a 0% cure rate. By 1 month after therapy, all placebo-treated patients demonstrated new lesions or one lesion that was 23% to 875% larger than before therapy. CONCLUSION:
|
Authors | R E Saenz, H Paz, J D Berman |
Journal | The American journal of medicine
(Am J Med)
Vol. 89
Issue 2
Pg. 147-55
(Aug 1990)
ISSN: 0002-9343 [Print] United States |
PMID | 2166429
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Gluconates
- Testosterone
- Ketoconazole
- Antimony Sodium Gluconate
|
Topics |
- Adolescent
- Adult
- Antimony Sodium Gluconate
(adverse effects, therapeutic use)
- Gluconates
(therapeutic use)
- Humans
- Ketoconazole
(adverse effects, therapeutic use)
- Leishmaniasis
(diagnosis, drug therapy)
- Male
- Middle Aged
- Randomized Controlled Trials as Topic
- Testosterone
(blood)
|